Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Genitourinary Cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate.

Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES

doi: 10.1002/pros.23955.

Genitourinary Cancer

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

J Clin Oncol.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O

doi: 10.1200/JCO.2016.72.1068.

Genitourinary Cancer

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

J Clin Oncol.

Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J

doi: 10.1200/JCO.2016.72.1076.

Genitourinary Cancer

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

Expert Rev Clin Pharmacol.

Vogelzang NJ

doi: 10.1080/

Genitourinary Cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging.

Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, Nitzsche E, Sundram F, Vogel W, Oyen W, Lewington V

doi: 10.1007/s00259-017-3756-7.

Genitourinary Cancer

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program

Clin Genitourin Cancer.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S Kühne R, Stenner F, Rothschild SI

doi: 10.1016/j.clgc.2016.06.011.

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Genitourinary Cancer

Therapy Management of Metastatic Prostate Carcinoma in General Practice

healthbook TIMES Oncology Hematology

Meisel A

doi: 10.36000/hbT.OH.2019.01.004

Genitourinary Cancer

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Eur Urol.

Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW

doi: 10.1016/j.eururo.2017.02.023.

Related content

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Therapy Management of Metastatic Prostate Carcinoma in General Practice

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer